Investor Ideas #Potcasts 627, #Cannabis News and #Stocks on the Move- Interview with CEO of Juva Life (CSE: $JUVA.C) (OTCQB: $JUVAF)
Delta, Kelowna, BC, March 11, 2022 (Investorideas.com Newswire), investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2022/031122-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2022/cannabis-potcasts/03111Interview-JUVA.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast Investorideas interviews Doug Chloupek, CEO of Juva Life Inc. (CSE: JUVA) (OTCQB:JUVAF) a cannabis cultivation and life sciences company aimed of unlocking the secret of pain management, where we discussed the company’s recent filing of a patent application with the United States Patent and Trademark Office (USPTO) on JUVA-041, a small molecule isolated from the cannabis plant that has been identified by Juva’s in-house research team, the potential applications of such small molecules, as well as where the industry is heading with regards to cannabinoid based research.
When asked about what helps differentiate Juva Life from other cannabinoid life sciences companies Chloupek commented, “Juva is a life science research company with heavy interest and focus on pharmaceutical new drug developments, specifically with small molecules targeting inflammation and unlocking the mysteries of cannabis. With that we have another arm of the company which really participates in the cannabis sector, so cultivation, distribution and delivery, and that’s really what supplies the revenue for the real fun of the company which is it’s life science portion.”
Chloupek went on to discuss his perspective on how the potential upside for the small molecules and life sciences portion of Juva far outweighs the strictly cannabis side of the industry saying, “what you have in the cannabis industry, with no disrespect to the cannabis industry because that’s where I come and that’s been my livelihood for over a decade, is you have thousands of companies and brands fighting for peanuts. When you’re looking at the pharmaceutical side of the industry it is almost largely untapped, besides a couple of multi-billion dollar acquisitions which have occurred of the last 12 months, and every single one of them are looking anxiously on the sidelines for how they can participate, but they can’ts because of federal restrictions, how they can get in, but they can’t because of regulatory burdens, and then you have Juva, threading a very complicated process and pathway, creating a new way that you can achieve similar end goals. Unequivocally the value is in the pharmaceutical drug development, the API development.”
Juva currently has two main small molecule patents in the works, JUVA-019 and JUVA-041. For JUVA-019 the Company has filed a patent application and has conducted preclinical research showing that the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. Through its research division, Juva scientists have continuously been evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit, leading to the identification of the two proprietary compounds: JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further preclinical investigation.
Speaking in more detail about the potential for these small molecules, Chloupek stated, “we have spent many many years and a lot of research, and I’ve put some of the smartest people in the world on a task, to understand the complexities of cannabis. How do you do that? How do you understand this complex plant that has thousands of different chemicals and identify down to what is the mode of action? We all know about the entourage effect which is the synergistic use of cannabinoids, terpenes and other chemical properties in cannabis which synergistically work together to create an effect on the human body. The question can then be asked, is there a particular single thing in the cannabis plant that we attribute as the entourage effect, or is it really necessary to have all of these other compounds synergistically working together? That's what distills down to the question of JUVA-019 and JUVA-041, is they are single molecule compounds found in cannabis, they are not terpenes, they are not cannabinoids they are not flavonoids, but they have been shown to be the key to the mode of action that regulates the pathways of inflammation in the human body found in cannabis.”
Chloupek continued, “So I can tell you for a fact, and this will be a mind blower for many listening, but THC and CBD, in relation to JUVA-041 and JUVA-019, hold little to no therapeutic value on inflammation in the human body, there is no added synergy, and for that matter combining THC or CBD or any other cannabinoids, downregulate the effectiveness of JUVA-019 and JUVA-041 down to the level of the respective cannabinoids. So they are exponentially more potent on their own, they regulate the cytokine pathways, and we are moving them through toxicology and safety through In Vivo right now.”
The company also recently announced the launch of the Company’s Journal App, designed to help cannabis users and patients track their consumption, and gain insight into how cannabis products affect their health and wellness.
“We’re proud to be one of the first and only companies to offer consumers a daily tracking solution that provides them a closer look at how their cannabis use affects their personal health and wellness,” said Doug Chloupek, CEO and Founder of Juva. “One of Juva’s primary goals is to expand our industry’s knowledge of the medicinal effects of cannabis from a scientific perspective. The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.”
Choupek went on to discuss in more detail some of the potential applications of JUVA-019 and JUVA-041 within the medical community, how he sees Juva’s business model influencing the industry as whole and what’s next on the horizon for Juva LIfe.
To find out more information about Juva Life Inc. click here.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms available.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
